The Interplay of Antigen Affinity, Internalization, and Pharmacokinetics on CD44-Positive Tumor Targeting of Monoclonal Antibodies

Molecular Pharmaceutics

Volumn 13, Issue 6, 2016, Pages 1894-1903

  Glatt, Dylan M ^a   Beckford Vera, Denis R ^b   Parrott, Matthew C ^b   Luft, J Christopher ^a   Benhabbour, S Rahima ^a   Mumper, Russell J ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

125I; A549; antibody characterization; biodistribution; CD44; cell uptake; cell surface binding; drug delivery; mAb; screening and selection; target engagement; tumor uptake

Indexed keywords

CD44V ANTIGEN; CELL SURFACE RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; HERMES ANTIGEN;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER STEM CELL; CONTROLLED STUDY; DRUG RETENTION; DRUG SCREENING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; A-549 CELL LINE; ANIMAL; IMMUNOLOGY; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE;

EID: 84973594920     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00063     Document Type: Article

References (53)

1. Weiner, L. M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 2010, 10, 317-326 10.1038/nri2744
2. Weiner, G. J. Building better monoclonal antibody-based therapeutics Nat. Rev. Cancer 2015, 15, 361-370 10.1038/nrc3930
3. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy Nat. Rev. Cancer 2002, 2, 750-763 10.1038/nrc903
4. Smaglo, B. G.; Aldeghaither, D.; Weiner, L. M. The development of immunoconjugates for targeted cancer therapy Nat. Rev. Clin. Oncol. 2014, 11, 637-648 10.1038/nrclinonc.2014.159
5. Shim, H. One target, different effects: a comparison of destine therapeutics antibodies against the same targets Exp. Mol. Med. 2011, 43 (10) 539-549 10.3858/emm.2011.43.10.063
6. Adams, G. P.; Schier, R.; Marshall, K.; Wolf, E. J.; McCall, A. M.; Marks, J. D.; Weiner, L. M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies Cancer Res. 1998, 58, 485-490
7. Adams, G. P.; Tai, M. S.; McCartney, J. E.; Marks, J. D.; Stafford, W. F., III; Houston, L. L.; Huston, J. S.; Weiner, L. M. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers Clin. Cancer Res. 2006, 12, 1599-1605 10.1158/1078-0432.CCR-05-2217
8. Muchekehu, R.; Liu, D.; Horn, M.; Campbell, L.; Del Rosario, J.; Bacica, M.; Moskowitz, H.; Osothprarop, T.; Dirksen, A.; Doppalapudi, V.; Kaspar, A.; Pirie-Shepherd, S. R.; Coronella, J. The effect of molecular weight, PK, and valency on tumor biodistribution and efficacy of antibody-based drugs Trans. Oncol. 2013, 6 (5) 562-572 10.1593/tlo.13409
9. Zhou, Y.; Goenaga, A.; Harms, B. D.; Zou, H.; Lou, J.; Conrad, F.; Adams, G. P.; Schoeberl, B.; Nielsen, U. B.; Marks, J. D. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies Mol. Cancer Ther. 2012, 11 (7) 1467-1476 10.1158/1535-7163.MCT-11-1038
10. Ritchie, M.; Bloom, L.; Carven, G.; Sapra, P. Selecting an optimal antibody for antibody-drug conjugate therapy Antibody-Drug Conjugates 2015, 17, 23-48 10.1007/978-3-319-13081-1-3
11. Adams, G. P.; Schier, R.; McCall, A. M.; Simmons, H. H.; Horak, E. M.; Alpaugh, R. K.; Marks, J. D.; Weiner, L. M. High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules Cancer Res. 2001, 61 (12) 4750-4755
12. Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-based tumor targeting Cancer Biother.Radiopharm. 2009, 24, 155-161 10.1089/cbr.2009.0627
13. Rudnick, S. I.; Lou, J.; Shaller, C. C.; Tang, Y.; Klein-Szanto, A. J. P.; Weiner, L. M.; Marks, J. D.; Adams, G. P. Influence of antigen affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors Cancer Res. 2011, 71 (6) 2250-2259 10.1158/0008-5472.CAN-10-2277
14. Langmuir, V. K.; Mendonca, H. L.; Woo, D. V. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: Uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids Cancer Res. 1992, 52, 4728-4734
15. Fujimori, K.; Covell, D. G.; Fletcher, J. E.; Weinstein, J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors Cancer Res. 1989, 49, 5656-5662
16. Fujimori, K.; Covell, D. G.; Fletcher, J. E.; Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier J. Nucl. Med. 1990, 31, 1191-1198
17. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors Cancer Res. 1990, 50, 814s-819s
18. Mager, D. E.; Jusko, W. J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J. Pharmacokinet. Pharmacodyn. 2001, 28 (6) 507-532 10.1023/A:1014414520282
19. Boswell, C. A.; Bumbaca, D.; Fielder, P. J.; Khawli, L. A. Compartmental tissue distribution of antibody therapeutics: Experimental approaches and interpretations AAPS J. 2012, 14 (3) 612-618 10.1208/s12248-012-9374-1
20. Ponta, H.; Sherman, L.; Herrlich, P. A. CD44: from adhesion molecules to signaling regulators Nat. Rev. Mol. Cell Biol. 2003, 4 (1) 33-45 10.1038/nrm1004
21. Naor, D.; Sionov, R. V.; Ish-Shalom, D. CD44: structure, function, and association with the malignant process Adv. Cancer Res. 1997, 71, 241-219 10.1016/S0065-230X(08)60101-3
22. Naor, D.; Nedvetzki, S.; Golan, I.; Melnik, L.; Faitelson, Y. CD44 in cancer Crit. Rev. Clin. Lab. Sci. 2002, 39 (6) 527-579 10.1080/10408360290795574
23. Naor, D.; Wallach-Dayan, S. B.; Zahalka, M. A.; Sionov, R. V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination Semin. Cancer Biol. 2008, 18 (4) 260-267 10.1016/j.semcancer.2008.03.015
24. Zoller, M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer 2011, 11 (4) 254-267 10.1038/nrc3023
25. Weigel, P. H.; McGary, C. T.; Weigel, J. A. Use of iodinated hyaluronan derivatives to study hyaluronan binding, endocytosis, and metabolism by cultured cells Methods Enzymol. 2003, 363, 382-391 10.1016/S0076-6879(03)01067-X
26. Marhaba, R.; Zoller, M. CD44 in cancer progression: adhesion, migration and growth regulation J. Mol. Histol. 2004, 35 (3) 211-231 10.1023/B:HIJO.0000032354.94213.69
27. Platt, V. M.; Szoka, F. C., Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor Mol. Pharmaceutics 2008, 5 (4) 474-486 10.1021/mp800024g
28. Sklar, L. A.; Finney, D. A. Analysis of ligand-receptor interactions with the fluorescence activated cell sorter Cytometry 1982, 3 (3) 161-165 10.1002/cyto.990030304
29. Waller, A.; Pipkorn, D.; Sutton, K. L.; Linderman, J. J.; Omann, G. M. Validation of flow cytometry competitive binding protocols and characterization of fluorescently labeled ligands Cytometry 2001, 45, 102-114 10.1002/1097-0320(20011001)45:2<102::AID-CYTO1152>3.0.CO;2-Z
30. Wojcicki, A. D.; Hillaireau, H.; Nascimento, T. L.; Arpicco, S.; Taverna, M.; Ribes, S.; Bourge, M.; Nicolas, V.; Bochot, A.; Vauthier, C.; Tsapis, N.; Fattal, E. Hyaluronic acid-bearing lipoplexes: Physico-chemical characterization and in vitro targeting of the CD44 receptor J. Controlled Release 2012, 162, 545-552 10.1016/j.jconrel.2012.07.015
31. Surace, C.; Arpicco, S.; Dufay-Wojcicki, A.; Marsaud, V.; Bouclier, C.; Clay, D.; Cattel, L.; Renoir, J.; Fattal, E. Lipoplexes targeting the CD44 hyaluronic acid receptor for efficient transfection of breast cancer cells Mol. Pharmaceutics 2009, 6 (4) 1062-1073 10.1021/mp800215d
32. Song, S.; Qi, H.; Xu, J.; Guo, P.; Chen, F.; Li, F.; Yang, X.; Sheng, N.; Wu, Y.; Pan, W. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting Pharm. Res. 2014, 31, 2988-3005 10.1007/s11095-014-1393-4
33. Alshaer, W.; Hillaireau, H.; Vergnaud, J.; Ismail, S.; Fattal, E. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells Bioconjugate Chem. 2015, 26 (7) 1307-1313 10.1021/bc5004313
34. Yu, Y. J.; Zhang, Y.; Kenrick, M.; Hoyte, K.; Luk, W.; Lu, Y.; Atwal, J.; Elliott, J. M.; Prabhu, S.; Watts, R. J.; Dennis, M. S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 2011, 3 (84) 84ra44 10.1126/scitranslmed.3002230
35. de Goeij, B. E.; Satijn, D.; Freitag, C. M.; Wubbolts, R.; Bleeker, W. K.; Khasanov, A.; Zhu, T.; Chen, G.; Miao, D.; van Berkel, P. H.; Parren, P. W. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates Mol. Cancer Ther. 2015, 14 (5) 1130-1140 10.1158/1535-7163.MCT-14-0798
36. Ackerman, M. E.; Pawlowski, D.; Wittrup, K. D. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther. 2008, 7 (7) 2233-2240 10.1158/1535-7163.MCT-08-0067
37. Qhattal, H. S. S.; Liu, X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes Mol. Pharmaceutics 2011, 8, 1233-1246 10.1021/mp2000428
38. Mattes, M. J.; Griffiths, G. L.; Diril, H.; Goldenberg, D. M.; Ong, G. L.; Shih, L. B. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells Cancer 1994, 73 (3) 787-793 10.1002/1097-0142(19940201)73:3+<787::AID-CNCR2820731307>3.0.CO;2-5
39. Press, O. W.; Shan, D.; Howell-Clark, J.; Eary, J.; Appelbaum, F. R.; Matthews, D.; King, D. J.; Haines, A. M.; Hamann, P.; Hinman, L.; Shochat, D.; Bernstein, I. D. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells Cancer Res. 1996, 56, 2123-2129
40. Owen, S. C.; Patel, N.; Logie, J.; Pan, G.; Persson, M.; Moffat, J.; Sidhu, S. S.; Shoichet, M. S. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles J. Controlled Release 2013, 172 (2) 395-404 10.1016/j.jconrel.2013.07.011
41. Ram, S.; Kim, D.; Ober, R. J.; Ward, E. S. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells mAbs 2014, 6 (5) 1211-1219 10.4161/mabs.29865
42. Hylander, B. L.; Punt, N.; Tang, H.; Hillman, J.; Vaughan, M.; Bshara, W.; Pitoniak, R.; Repasky, E. A. Origin of the vasculature supporting growth of primary patient tumor xenografts J. Transl. Med. 2013, 11 (110) 110 10.1186/1479-5876-11-110
43. Hagan, P. L.; Halpern, S. E.; Dillman, R. O.; Shawler, D. L.; Johnson, D. E.; Chen, A.; Krishnan, L.; Frincke, J.; Bartholomew, R. M.; David, G. S.; Carlo, D. Tumor size: effect of monoclonal antibody uptake in tumor models J. Nucl. Med. 1986, 27 (3) 422-427
44. Alitalo, A.; Detmar, M. Interaction of tumor cells and lymphatic vessels in cancer progression Oncogene 2012, 31, 4499-4508 10.1038/onc.2011.602
45. Alitalo, K. The lymphatic vasculature in disease Nat. Med. 2011, 17, 1371-1380 10.1038/nm.2545
46. Kennel, S. J.; Lankford, T. K.; Foote, L. J.; Shinpock, S. G.; Stringer, C. CD44 expression on murine tissues J. Cell Sci. 1993, 104, 373-382
47. Vugts, D. J.; Heuveling, D. A.; Stigter-van Walsum, M.; Weigand, S.; Bergstrom, M.; van Dongen, G. A.; Nayak, T. K. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to phase I clinical studies mAbs 2014, 6 (2) 567-575 10.4161/mabs.27415
48. Kijanka, G.; Prokopowicz, M.; Schellekens, H.; Brinks, V. Influence of aggregation and route of injection on the biodistribution of mouse serum albumin PLoS One 2014, 9 (1) e85281 10.1371/journal.pone.0085281
49. Filipe, V.; Que, I.; Carpenter, J. F.; Lowik, C.; Jiskoot, W. In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice Pharm. Res. 2014, 31 (1) 216-227 10.1007/s11095-013-1154-9
50. Graff, C. P.; Wittrup, K. D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention Cancer Res. 2003, 63 (6) 1288-1296
51. Thurber, G. M.; Zajic, S. C.; Wittrup, K. D. Theoretic criteria for antibody penetration into solid tumors and micrometastases J. Nucl. Med. 2007, 48 (6) 995-999 10.2967/jnumed.106.037069
52. Vasalou, C.; Helmlinger, G.; Gomes, B. A mechanistic tumor penetration model to guide antibody drug conjugate design PLoS One 2015, 10 (3) e0118977 10.1371/journal.pone.0118977
53. Sadekar, S.; Figueroa, I.; Tabrizi, M. Antibody drug conjugates: Application of quantitative pharmacology in modality design and target selection AAPS J. 2015, 17 (4) 828-836 10.1208/s12248-015-9766-0